Masaki Shiota1, Motonobu Nakamura2, Akira Yokomizo3, Toshihisa Tomoda4, Naotaka Sakamoto5, Narihito Seki6, Shuji Hasegawa7, Takakazu Yunoki8, Masahiko Harano9, Kentaro Kuroiwa10, Masatoshi Eto11. 1. Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan shiota@uro.med.kyushu-u.ac.jp. 2. Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. 3. Division of Urology, Harasanshin Hospital, Fukuoka, Japan. 4. Department of Urology, Oita Prefectural Hospital, Oita, Japan. 5. Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 6. Department of Urology, Kyushu Central Hospital, Fukuoka, Japan. 7. Department of Urology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan. 8. Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan. 9. Department of Urology, JCHO Kyushu Hospital, Kitakyushu, Japan. 10. Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan. 11. Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND/AIM: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. PATIENTS AND METHODS: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. RESULTS: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. CONCLUSION: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the post-docetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy. Copyright
BACKGROUND/AIM: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. PATIENTS AND METHODS: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. RESULTS: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. CONCLUSION: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the post-docetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy. Copyright